Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this module, Charise Gleason, MSN, NP-BC, AOCNP; Sagar Lonial, MD; and Kathryn Maples, PharmD, BCOP, provide their perspectives on the evolving treatment landscape for multiple myeloma (MM) in 2020, including management options for patients with newly diagnosed smoldering or active MM, treatment selection for patients with relapsed/refractory (R/R) disease, and evolving data on promising new therapies on the horizon.
This educational activity also reviews treatment recommendations from a Clinical Care Options online interactive treatment decision tool for MM developed by 5 experts: Sarah A. Holstein, MD, PhD; Carol Ann Huff, MD; Shaji Kumar, MD; Sagar Lonial, MD; and Peter M. Voorhees, MD. This tool allows you to enter your specific patient’s characteristics and then provides treatment recommendations from the 5 experts. To access this tool, please click here.
The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset that can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.
Clinical Care Options plans to measure the educational impact of this activity. A couple of questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.
Before continuing with this educational activity, please take a moment to answer the following questions.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.